WHO’s Interim recommendations for the use of One-dose Janssen Ad26.COV2.S (COVID-19) vaccine


Share post:

Single dose of the vaccine can increase vaccine coverage rapidly which is an imperative in many countries where level of vaccine uptake is not optimal.  

WHO has updated its interim recommendations1 on the use of the Janssen Ad26.COV2.S (COVID-19).

One-dose schedule of the Janssen vaccine:  

Use of either a one- or two-course of the Janssen vaccine can now be considered.  

The one-dose schedule is an EUL (Emergency Use Listing) authorized regimen. 

In some circumstances, using one dose may have advantages.  Many countries face severe vaccine supply constraints, combined with a high disease burden.  A single dose of the vaccine is efficacious and makes it possible to increase vaccine coverage rapidly, which in turn will reduce the burden on health care systems by preventing severe disease outcomes. A single dose may also be a preferred option for vaccinating hard-to-reach populations or populations living in conflict or insecure settings. 

Second dose of the vaccine:  

A second dose may be appropriate as vaccine supplies and/or accessibility increases. Countries should consider offering a second dose, beginning with the highest priority populations (e.g., healthcare workers, older people, people with comorbidities) as indicated in the WHO Prioritization Roadmap.  The administration of the second dose will result in increased protection against symptomatic infection, and against severe disease. 

A heterologous vaccine (e.g., a COVID-19 vaccine from another vaccine platform that has received EUL) can also be considered for the second dose. 

Interval between doses:  

Countries can also consider a longer interval between doses. A second dose 2 months after the initial dose substantially increases efficacy, especially against symptomatic infections, including when caused by SARS-CoV-2 variants of concern.  An even longer interval between the two doses with Ad26.COV2.S (6 months rather than 2 months) has been shown to result in a larger increase in immune responses in adults.  Countries could therefore consider an interval of up to 6 months based on their epidemiological situation, and needs of sub-populations. 


Like Oxford/AstraZeneca’s ChAdOx1, Janssen Ad26.COV2.S (COVID-19) vaccine also uses adenoviruses as vectors. There are evidences to link them to rare side effects of blood clot as they bind to platelet factor 4 (PF4), a protein implicated in the pathogenesis of clotting disorders2



  1. WHO 2021. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. Interim guidance Updated 9 December 2021. Available online at https://apps.who.int/iris/rest/bitstreams/1398839/retrieve  
  1. Soni R., 2021.Future of Adenovirus based COVID-19 Vaccines (such as Oxford AstraZeneca) in light of recent finding about Cause of rare side effects of Blood clot. Scientific European. Posted 03 December 2021. Available online here  


SCIEU Teamhttp://www.ScientificEuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.


Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

For the benefit of students and readers (neural translation of) Scientific European is available in many languages

Deutsch Română
Français Nederlands
Русский Português
简体中文 Italiano
日本語 Български
Español Filipino
हिन्दी ગુજરાતી
العربية தமிழ்
Ελληνικά اردو
বাংলা MORE

Related articles

Stem Cell Models of Diseases: First Model of Albinism Developed

Scientists have developed the first patient-derived stem cell model of albinism. The model will help studying eye conditions...

Mars Orbiter Mission (MOM) of ISRO: New Insight into Prediction of Solar Activity

The researchers have studied the turbulence in Sun’s corona using radio signals sent to Earth by the ultra-low-cost...

‘‘A living WHO guideline on drugs for COVID-19’’: The Eighth version (Seventh update) Released

The eighth version (seventh update) of a living guideline is released. It replaces earlier versions. The latest update...

….Pale Blue Dot, the only Home We’ve Ever Known

''....astronomy is a humbling and character-building experience. There is perhaps no better demonstration of the folly of human...